Friday, July 31, 2026

US-Iran Ceasefire: What It Means for Shipping in the Strait of Hormuz

The U.S.-Iran ceasefire allows for safer shipping through the Strait of Hormuz, with hopes for lasting peace in the Middle East.

HM15275 Clinical Trials: What You Need to Know About This Groundbreaking Obesity Treatment

Hanmi Pharmaceutical's HM15275 enters Phase 2 trial, aiming to revolutionize obesity treatment and diabetes management by 2030.

Kim Jong Un Heads to Beijing as China, Russia, and North Korea Tighten Their Alliance

Kim Jong Un's visit to China for the Victory Day celebration aims to strengthen ties with China and Russia, promoting a new international order.

Tag: Oncology

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

HLB PEP Achieves FDA Registration for Vasopressin API: What This Means for Global Markets

HLB PEP has registered Vasopressin API with the FDA, aiming for global market entry and expanding its peptide portfolio.

Hanmi Pharmaceutical completes acquisition of Aptose Biosciences

Hanmi Pharmaceutical has acquired Aptose Biosciences for $46.7 million, regaining rights to the cancer drug tuspetinib.

Celltrion’s Truxima becomes first rituximab biosimilar in U.S. to receive interchangeability designation

Celltrion's Truxima gains FDA interchangeability status, enhancing its market position and credibility in blood cancer treatment.

LegoChem expands options beyond early ADC licensing into late-stage clinical development

LegoChem Biosciences secures funding to advance ADC therapies into late-stage trials, enhancing strategic flexibility in biotech.

Seoul Asan Hospital Dominates Newsweek’s 2026 Asia-Pacific Rankings: 5 Clinical Areas at #1!

Seoul Asan Medical Center ranks first in five specialties in Newsweek's 2026 Asia-Pacific Best Hospitals, showcasing its medical excellence.

Celltrion Launches New Cancer Drugs in Vietnam: What You Need to Know

Celltrion launched two cancer treatments in Vietnam, expanding its portfolio and aiming for aggressive sales growth in the region.

ABL Bio to Showcase Dual-Target ADC Candidate ABL209 at World ADC Korea 2026

ABL Bio will showcase its dual-target ADC candidate ABL209 at the World ADC Korea 2026, focusing on enhanced cancer treatment.

Sillajen Presents Early BAL0891 Clinical Findings at ASCO 2026, Highlighting Safety and Early Anti-Cancer Activity

ShillaGen presented initial clinical research results of its cancer drug BAL0891 at ASCO, showcasing promising developments.

FDA Approval Allows AlphaTau to Broaden IMPACT Trial in Pancreatic Cancer

AlphaTau Medical expands its pancreatic cancer trial with FDA approval, adding 10 patients for a combination treatment approach.

Korea’s First Domestic CAR-T Therapy Just Won Approval—and That’s a Bigger Deal Than It Sounds

CureCell's CAR-T therapy Rimkato is the first approved in South Korea, enhancing access to treatment for blood cancer patients.

Unlocking Cancer Treatment: Celltrion’s 4 Promising ADC Drugs Enter Patient Trials in 2026

Celltrion's ADC cancer drug candidates CT-P70, CT-P71, and CT-P73 enter patient dosing, targeting various cancers with Fast Track Designation.

Next-Gen Cancer Drug Nesuparib: How It Outperforms Olaparib in SCLC and Pancreatic Cancer

Onconic Therapeutics will present Nesuparib research at AACR 2026, showcasing its potential for various cancers and overcoming PARP inhibitor limitations.

Proton Therapy for Liver Cancer: Revolutionary Results from Samsung Medical Center

Samsung Medical Center's proton therapy shows high effectiveness for liver cancer, offering hope for patients unsuitable for standard treatments.

SK Biopharmaceuticals Unveils Breakthrough Findings on NTSR1-Targeted Radiopharmaceutical SKL35501

SK Biopharmaceuticals will present findings on NTSR1-targeted treatments at the AACR Annual Meeting, showcasing innovative oncology research.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.